Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review

Gianluca Ingrosso, Carlotta Becherini, Giulio Francolini, Andrea Lancia, Emanuele Alì, Saverio Caini, Maria Ausilia Teriaca, Alessandro Marchionni, Andrea Riccardo Filippi, Lorenzo Livi, Giuseppe Sanguineti, Cynthia Aristei, Beatrice Detti

Research output: Contribution to journalReview articlepeer-review


Objective: To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles. Evidence acquisition: We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool. Evidence synthesis: A total of 6 studies were included, corresponding to a cohort of 216 patients. Tyrosine Kinases Inhibitors were the most widely used drugs in combination with SBRT, being administered in 93% patients. No study reported an increase of radiation-induced toxicity. Conclusions: SBRT resulted to be safe, without increase in terms of drugs-related adverse events in this setting. Moreover, this approach showed promising clinical outcomes in terms of LC and OS

Original languageEnglish
Article number103242
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Mar 2021


  • Immunotherapy
  • Renal cancer
  • Stereotactic radiotherapy
  • Target therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review'. Together they form a unique fingerprint.

Cite this